Bagsværd, Denmark, 31 January 2020 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Rybelsus (oral semaglutide) for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise.
The CHMP recommends Rybelsus to be indicated as monotherapy when metformin is considered inappropriate, as well as in combination with other medicinal products for the treatment of type 2 diabetes. The label also refers to clinical trial results with respect to combination with other diabetes medications, effects on glycaemic control, cardiovascular events and the populations studied.
"We are very excited about the positive opinion for Rybelsus, as it is the first and only GLP-1 in a tablet, and we believe it has the potential to set a new standard for the treatment of type 2 diabetes in the EU," said Mads Krogsgaard Thomsen, executive vice president and chief science officer. "A high proportion of people with type 2 diabetes does not achieve target blood sugar levels, which underpins the need for new and more efficacious solutions to better manage their disease."
Novo Nordisk expects to receive final marketing authorisation from the European Commission in the beginning of second quarter of 2020.
About Rybelsus
Rybelsus (oral semaglutide) is an analogue of the naturally occurring hormone GLP-1, and it is the world's first and only GLP-1 in a tablet. Rybelsus is approved in the US and it is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It is administered once daily and is approved for use in two therapeutic dosages, 7 mg and 14 mg in the US.
Further information
| Media: | ||
| Mette Kruse Danielsen | +45 4442 3883 | mkd@novonordisk.com (mailto:mkd@novonordisk.com) |
| Ken Inchausti (USA) | +1 609 240 9429 | kiau@novonordisk.com (mailto:kiau@novonordisk.com) |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com (mailto:phak@novonordisk.com) |
| Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com (mailto:jvls@novonordisk.com) |
| Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com (mailto:arnd@novonordisk.com) |
| Mark Joseph Root | +45 3079 4211 | mjhr@novonordisk.com (mailto:mjhr@novonordisk.com) |
| Kristoffer Due Berg (USA) | +1 609 235 2989 | krdb@novonordisk.com (mailto:krdb@novonordisk.com) |
Company announcement No 5 / 2020
Attachment
- PR200131_Rybelsus_CHMP_opinion (https://ml-eu.globenewswire.com/Resource/Download/0c64bd8a-a0e0-4fdd-8e39-ddd41087236a)
